Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites

Nicholas Bodor, Peter Buchwald

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Integration metabolic considerations into the drug-design process can allow safer pharmaceuticals to be designed. "Soft" drugs are designed to be deactivated in a predictable and controllable way after achieving their therapeutic role. They are designed to be metabolized rapidly and by avoiding oxidative pathways into inactive and nontoxic species. Successful application of such design principles has already resulted in a number of marketed drugs. The present article illustrates advantages inherent in avoiding the formation of oxidative metabolites, with examples that include soft bufuralol analogs and soft insecticides such as chlorobenzilate and malathion. Design principles for various soft drug classes are briefly summarized together with computerized tools intended to make the application of these principles more quantitative and more accessible.

Original languageEnglish
Pages (from-to)123-132
Number of pages10
JournalApplied Biochemistry and Biotechnology - Part B Molecular Biotechnology
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Poisons
Metabolites
Pharmaceutical Preparations
Insecticides
Malathion
Drug products
Drug Design
Therapeutics

Keywords

  • Active metabolite
  • Bufuralol
  • Ester hydrolases
  • Inactive metabolite
  • Malathion
  • Structure-metabolism relationship

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering

Cite this

@article{b4f2095f13e148ceaba7fc8f81dafc5e,
title = "Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites",
abstract = "Integration metabolic considerations into the drug-design process can allow safer pharmaceuticals to be designed. {"}Soft{"} drugs are designed to be deactivated in a predictable and controllable way after achieving their therapeutic role. They are designed to be metabolized rapidly and by avoiding oxidative pathways into inactive and nontoxic species. Successful application of such design principles has already resulted in a number of marketed drugs. The present article illustrates advantages inherent in avoiding the formation of oxidative metabolites, with examples that include soft bufuralol analogs and soft insecticides such as chlorobenzilate and malathion. Design principles for various soft drug classes are briefly summarized together with computerized tools intended to make the application of these principles more quantitative and more accessible.",
keywords = "Active metabolite, Bufuralol, Ester hydrolases, Inactive metabolite, Malathion, Structure-metabolism relationship",
author = "Nicholas Bodor and Peter Buchwald",
year = "2004",
month = "2",
day = "1",
doi = "10.1385/MB:26:2:123",
language = "English",
volume = "26",
pages = "123--132",
journal = "Molecular Biotechnology",
issn = "1073-6085",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites

AU - Bodor, Nicholas

AU - Buchwald, Peter

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Integration metabolic considerations into the drug-design process can allow safer pharmaceuticals to be designed. "Soft" drugs are designed to be deactivated in a predictable and controllable way after achieving their therapeutic role. They are designed to be metabolized rapidly and by avoiding oxidative pathways into inactive and nontoxic species. Successful application of such design principles has already resulted in a number of marketed drugs. The present article illustrates advantages inherent in avoiding the formation of oxidative metabolites, with examples that include soft bufuralol analogs and soft insecticides such as chlorobenzilate and malathion. Design principles for various soft drug classes are briefly summarized together with computerized tools intended to make the application of these principles more quantitative and more accessible.

AB - Integration metabolic considerations into the drug-design process can allow safer pharmaceuticals to be designed. "Soft" drugs are designed to be deactivated in a predictable and controllable way after achieving their therapeutic role. They are designed to be metabolized rapidly and by avoiding oxidative pathways into inactive and nontoxic species. Successful application of such design principles has already resulted in a number of marketed drugs. The present article illustrates advantages inherent in avoiding the formation of oxidative metabolites, with examples that include soft bufuralol analogs and soft insecticides such as chlorobenzilate and malathion. Design principles for various soft drug classes are briefly summarized together with computerized tools intended to make the application of these principles more quantitative and more accessible.

KW - Active metabolite

KW - Bufuralol

KW - Ester hydrolases

KW - Inactive metabolite

KW - Malathion

KW - Structure-metabolism relationship

UR - http://www.scopus.com/inward/record.url?scp=3042687583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042687583&partnerID=8YFLogxK

U2 - 10.1385/MB:26:2:123

DO - 10.1385/MB:26:2:123

M3 - Article

C2 - 14764938

AN - SCOPUS:3042687583

VL - 26

SP - 123

EP - 132

JO - Molecular Biotechnology

JF - Molecular Biotechnology

SN - 1073-6085

IS - 2

ER -